Drug Trial Radar · NCT04884191
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Last checked: Nov 20, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Jul 31, 2017
Primary completion
Sep 4, 2019
Study completion Sep 4, 2019
Sponsor
- Lead sponsor
- CTI BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Conditions
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post- Essential Thrombocythemia Myelofibrosis
Interventions
PacritinibDrug
Pacritinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen Volume Reduction Response (≥ 35%)Time frame: From Baseline to Weeks 12 and 24
- Percent Change in Spleen VolumeTime frame: From Baseline to Weeks 12 and 24
- Total Symptom Score AnalysisTime frame: From Baseline to Weeks 12 and 24
- Patient Global Impression AssessmentTime frame: From Baseline to Weeks 12 and 24
Locations
62 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope
Duarte, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
Stanford Cancer Institute
Stanford, California
Yale School of Medicine
New Haven, Connecticut
Medical Faculty Associates, Inc.
Washington D.C., District of Columbia
Florida Cancer Specialists & Research Institute
Fort Myers, Florida
Florida Cancer Specialists & Research Institute
St. Petersburg, Florida
Florida Cancer Specialists & Research Institute
West Palm Beach, Florida
Northwestern University Feinberg School of Medicine
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
University of Kansas Cancer Center
Westwood, Kansas
Ochsner Medical Center
New Orleans, Louisiana
Saint Agnes Hospital
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Washington University School of Medicine in St. Louis
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Weill Cornell Medical College
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
University of Rochester
Rochester, New York
Duke University Hospital
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Tennessee Oncology
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Texas Health Science Center at San Antonio School of Medicine
San Antonio, Texas
University of Utah School of Medicine
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
CHU Hopital Sud
Amiens, France
Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez
Lille, France
CHU de Nimes - Hopital Universitaire Caremeau
Nîmes, France
Hôpital Saint-Louis
Paris, France
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
Pessac, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Centre Hospitalier Universitaire de Toulouse- Hôpital Purpan
Toulouse, France
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.